



Chronix Biomedical to present clinical data on its cell-free DNA approach as an early predictor of response to chemotherapy at the AACR Annual Meeting

San Jose, CA, USA and Göttingen, Germany (March 17, 2016) - Chronix Biomedical, Inc., announces today that the first clinical data on one of its development programs, a cell-free DNA molecular diagnostic test for prediction of response to chemotherapy, will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting. The 2016 AACR meeting will take place on 16-20 April at the Ernest N. Morial Convention Center, New Orleans, Louisiana, USA.

The study is entitled *Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers (Abstract #3138)* and will be presented from 08:00-12:00 CDT at Poster Section 22 on 19 April 2016.

The abstract, which has just been published online, describes the work of Chronix Biomedical to establish a relationship between copy number instability, measured from circulating cell-free DNA, and a patient's response to cytotoxic chemotherapy. Data on 24 patients with five different tumour types will be shown, which suggest that it is possible with high confidence to identify early those who will respond to treatment from those who will progress despite treatment.

Further details on the work will be disclosed once the poster has been presented.

Chronix Biomedical's CEO Dr Howard B. Urnovitz commented: "We are pleased to be able to present our work on copy number instability and treatment response in these cancers at this prestigious scientific meeting. We look forward to conducting further work to validate this molecular diagnostic test and intend to make this test available to clinicians as soon as possible."

Dr Nick Plowman, Senior Consultant Physician and Clinical Oncologist to St. Bartholomew Hospital and The Hospital for Sick Children, London, UK, and an independent scientific advisor to Chronix Biomedical said: "A simple blood test, such as this, can reliably and quickly identify, which patients will respond to chemotherapy. Faster and better than the current standard of care of scanning, this treatment assessment should help oncologists to consider therapeutic options with new critical information. This blood test will greatly benefit patients while supporting healthcare providers to better allocate scarce healthcare resources."

About Chronix Biomedical

Chronix Biomedical, Inc. is a US-based molecular diagnostics company developing blood tests primarily for the screening and monitoring of cancer. Chronix already offers prognostic tests based on copy number instability for breast and prostate cancer through its own certified laboratories in Göttingen. The prostate cancer test can discriminate between prostate cancer and other prostate conditions (such as benign prostatic hypertrophy and prostatitis) thereby avoiding invasive needle biopsies. These Chronix supplementary tests assist oncologists in making cancer diagnoses and can reduce costs to healthcare providers by preventing unnecessary procedures such as tissue biopsies. For more information visit www.chronixbiomedical.com.



Contacts

Chronix Biomedical, Inc
Dr Howard Urnovitz, CEO

+49 1515 259 3383
hbu@chronixbiomedical.de

Shard Capital Partners LLP
(Corporate Adviser and Broker)
Dr Wang Chong

+44 20 7186 9948
wang.chong@shardcapital.com